Hyderabad based Biophore India gets DCGI nod to manufacture COVID drug Favipiravir - (The Economic Times via NewsPoints Desk)

  • Biophore India Pharmaceuticals received license from the Drug Controller General of India (DCGI) to manufacture favipiravir, a drug used to treat mild to moderate cases of COVID-19, as reported The Economic Times on Tuesday.

  • Besides DCGI's approval to produce the active pharmaceutical ingredient (API) in India, it has been cleared for exports too.

  • Biophore India said that it has also received approval in Turkey to export the API in collaboration with a local partner and is in talks with several Indian partners to commercialise the product in India, and is in talks with Bangladesh and Egypt-based companies for its export.

  • Chief scientist officer Manik Reddy Pullagurla said that "and we have the capacity to scale up production to meet local requirements, without compromising on our export commitments."

To read more NewsPoints articles, click here.